在患有不可切除的形甲状腺癌的患者中,初始林瓦替尼治疗的结果
Hiroyuki Iwasaki1, Soji Toda1, Akari Takahashi1
1Department of Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
Oncology letters
|August 24, 2023
概括
与帕克利塔塞尔相比,伦瓦提尼布单独治疗可以改善甲状腺癌 (ATC) 患者的生存率. 这种初始治疗策略在阻止这种罕见而侵袭性癌症的疾病进展方面显示出有希望.
科学领域:
- 在瘤学瘤学.
- 甲状腺癌研究研究
背景情况:
- 无塑性甲状腺癌 (ATC) 异常罕见,预后不佳.
- 目前,对于ATC没有普遍有效的药物治疗方法.
研究的目的:
- 为了评估lenvatinib作为不可切除的ATC的初始单疗法的结果,安全性和有效性.
- 为了比较伦瓦提尼布与帕克利塔克塞尔和最佳支持性护理的有效性.
主要方法:
- 追溯性队列研究,对56名无法切除的初级ATC患者进行了研究.
- 治疗组包括伦瓦提尼布 (36名患者),每周服用帕克利塔塞尔 (12名患者) 和息治疗 (8名患者).
主要成果:
- 伦瓦替尼布组的平均存活时间 (5.8个月) 比帕克利塔塞尔 (2.0个月;P=0.005) 显著更长.
- 在伦瓦替尼布组中,应答率为33%,平均整体存活时间为5.0个月.
- 两名患者通过使用伦瓦提尼布实现了瘤减少,使转换手术成为可能,尽管完全缓解仍然难以捉摸.
结论:
- 伦瓦提尼布单一治疗是不可切除的ATC的可行的初始治疗策略,可以改善存活率并阻止疾病的进展.
- 由于伦瓦提尼布的潜在局部副作用,需要仔细监测.
- 将伦瓦提尼布与基因组分析结合用于随后的治疗选择是ATC管理的一个有希望的方法.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K